Cargando…
REDD1 functions at the crossroads between the therapeutic and adverse effects of topical glucocorticoids
Cutaneous atrophy is the major adverse effect of topical glucocorticoids; however, its molecular mechanisms are poorly understood. Here, we identify stress-inducible mTOR inhibitor REDD1 (regulated in development and DNA damage response 1) as a major molecular target of glucocorticoids, which mediat...
Autores principales: | Baida, Gleb, Bhalla, Pankaj, Kirsanov, Kirill, Lesovaya, Ekaterina, Yakubovskaya, Marianna, Yuen, Kit, Guo, Shuchi, Lavker, Robert M, Readhead, Ben, Dudley, Joel T, Budunova, Irina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309667/ https://www.ncbi.nlm.nih.gov/pubmed/25504525 http://dx.doi.org/10.15252/emmm.201404601 |
Ejemplares similares
-
Sexual dimorphism in atrophic effects of topical glucocorticoids is driven by differential regulation of atrophogene REDD1 in male and female skin
por: Baida, Gleb, et al.
Publicado: (2020) -
The long winding road to the safer glucocorticoid receptor (GR) targeting therapies
por: Lesovaya, Ekaterina A., et al.
Publicado: (2022) -
Important role of kallikrein 6 for the development of keratinocyte proliferative resistance to topical glucocorticoids
por: Kishibe, Mari, et al.
Publicado: (2016) -
Nutritional Sensor REDD1 in Cancer and Inflammation: Friend or Foe?
por: Zhidkova, Ekaterina M., et al.
Publicado: (2022) -
Deletion of the glucocorticoid receptor chaperone FKBP51 prevents glucocorticoid-induced skin atrophy
por: Baida, Gleb, et al.
Publicado: (2018)